Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach